Skip to main content

Advertisement

SpringerLink
Log in

Biopharmaceutical benchmarks 2014

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Approvals by region and by date.
Figure 2: mAbs approved within the indicated periods, expressed as a percentage of total biopharmaceutical product approvals within the same period.
Figure 3: Product approvals, cumulative (1982–2014) and for the current period (2010–July 2014) in the context of product class.
Figure 4
Figure 5: Expression systems used to manufacture biopharmaceutical products.

References

  1. Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24, 769–776 (2006).

    Article  CAS  Google Scholar 

  2. Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).

    Article  CAS  Google Scholar 

  3. Blackstone, E. & Fuhr, J. The Economics of biosimilars. American Health and Drug Benefits (July 2, 2014).

    Google Scholar 

  4. Rickwoood, S. & Di Biase, S. Searching for Terra Firma in the Biosimilars and Non-Original Biologics Market (IMS Health, Parsippany, NJ, USA, 2013).

    Google Scholar 

  5. Hospira Reports on success of its biosimilar proteins in Europe and Australia, La Meire Biologics 6, 3–4 (2013).

  6. Dalgaard, K. et al. Biosimilars Seven Years On: Where are We and What's Next? (McKinsey and Company, New York, NY, USA, 2013).

    Google Scholar 

  7. Perez, H.L. et al. Antibody–drug conjugates: current status and future directions. Drug Discov. Today 19, 869–881 (2014).

    Article  CAS  Google Scholar 

  8. Goede, V. et al. Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results of the CLL11 Trial. Presented at the 55th ASH Annual Meeting and Exposition. New Orleans, LA. December 7-10, 2013. Abstract 6.

  9. Nielsen, L.S. et al. Single-batch production of recombinant human polyclonal antibodies. Mol. Biotechnol. 45, 257–266 (2010).

    Article  CAS  Google Scholar 

  10. Kling, J. Sanofi to propel inhaled insulin Afrezza to market. Nat. Biotechnol. 32, 851–852 (2014).

    Article  CAS  Google Scholar 

  11. Kwon, K.C. et al. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65, 782–799 (2013).

    Article  CAS  Google Scholar 

  12. Emerton, D.A. Profitability in the biosimilars market: can you translate scientific excellence into a healthy commercial return? Bioprocess Int. 11, 6–14 (2013).

    Google Scholar 

  13. Brennan, T.A. & Wilson, J.M. The special case of gene therapy pricing. Nat. Biotechnol. 32, 874–876 (2014).

    Article  CAS  Google Scholar 

  14. PhRMA. Medicines in Development: Biologics. 2013 report. http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf (PhRMA, Washington, DC, 2013)

  15. Olinger, G.G. et al. Delay treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus monkeys. Proc. Natl. Acad. Sci. USA 109, 18030–18035 (2012).

    Article  CAS  Google Scholar 

  16. Qui, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 10.1038/nature13777 (29 August 2014).

  17. Broz, A., Huang, N. & Unruh, G. Plant-based protein biomanufacturing. Genet. Eng. Biotechnol. News 33, 32–33 (2013).

    Article  Google Scholar 

  18. Beck, A. & Reichert, J.M. Approval of the first biosimilar antibodies in Europe. MAbs 5, 621–623 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical and Environmental Sciences, Gary Walsh is at the Industrial Biochemistry Program, University of Limerick, Ireland, and the Materials and Surface Science Institute, University of Limerick, Ireland.,

    Gary Walsh

Authors
  1. Gary Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary Walsh.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary Table 1

New traditional-type biotech product* approvals 2010-2014. (PDF 161 kb)

Supplementary Table 2

Stem cell products in phase 3 clinical trials (PDF 50 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walsh, G. Biopharmaceutical benchmarks 2014. Nat Biotechnol 32, 992–1000 (2014). https://doi.org/10.1038/nbt.3040

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3040

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation